CL2021003373A1 - Nuevos inhibidores de egfr - Google Patents

Nuevos inhibidores de egfr

Info

Publication number
CL2021003373A1
CL2021003373A1 CL2021003373A CL2021003373A CL2021003373A1 CL 2021003373 A1 CL2021003373 A1 CL 2021003373A1 CL 2021003373 A CL2021003373 A CL 2021003373A CL 2021003373 A CL2021003373 A CL 2021003373A CL 2021003373 A1 CL2021003373 A1 CL 2021003373A1
Authority
CL
Chile
Prior art keywords
egfr inhibitors
new egfr
new
compounds
inhibitors
Prior art date
Application number
CL2021003373A
Other languages
English (en)
Inventor
Annick Goergler
Georg Jaeschke
Bernd Kuhn
Yvonne Alice Nagel
Antonio Ricci
Daniel Rueher
Sandra Steiner
Cosimo Dolente
David Stephen Hewings
Roger David Norcross
Christa Ulrike Obst-Sander
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2021003373A1 publication Critical patent/CL2021003373A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

La invención proporciona nuevos compuestos como se describen en la presente, composiciones que incluyen los compuestos y métodos para usar los compuestos.
CL2021003373A 2019-06-21 2021-12-16 Nuevos inhibidores de egfr CL2021003373A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19181772 2019-06-21

Publications (1)

Publication Number Publication Date
CL2021003373A1 true CL2021003373A1 (es) 2022-10-07

Family

ID=67001684

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003373A CL2021003373A1 (es) 2019-06-21 2021-12-16 Nuevos inhibidores de egfr

Country Status (19)

Country Link
US (2) US20220315591A1 (es)
EP (2) EP3986566B1 (es)
JP (2) JP2022537772A (es)
KR (1) KR20220024096A (es)
CN (2) CN113993591A (es)
AR (2) AR119207A1 (es)
AU (1) AU2020296933A1 (es)
BR (1) BR112021024810A2 (es)
CA (1) CA3139171A1 (es)
CL (1) CL2021003373A1 (es)
CO (1) CO2021016967A2 (es)
CR (1) CR20210614A (es)
IL (1) IL287806A (es)
MA (1) MA56507A (es)
MX (1) MX2021015889A (es)
PE (1) PE20220807A1 (es)
TW (2) TW202115073A (es)
WO (2) WO2020254547A1 (es)
ZA (1) ZA202108775B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2408932T3 (es) 2008-06-25 2013-06-24 Merck Sharp & Dohme Corp. Síntesis y uso de agentes antibacterianos heterocíclicos
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
BR112017024481B1 (pt) 2015-05-14 2020-11-17 The Wistar Institute Of Anatomy And Biology composto inibidor de ebna1, composição farmacêutica compreendendo dito composto e usos terapêuticos do mesmo
CA2987914C (en) * 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibitors of egfr and methods of use thereof
AR113299A1 (es) * 2017-06-02 2020-04-08 Hoffmann La Roche Compuestos de isoindolina
KR20210025535A (ko) * 2018-06-29 2021-03-09 에프. 호프만-라 로슈 아게 화합물

Also Published As

Publication number Publication date
WO2020254546A1 (en) 2020-12-24
EP3986567C0 (en) 2023-08-30
TW202115070A (zh) 2021-04-16
EP3986566C0 (en) 2023-08-30
TW202115073A (zh) 2021-04-16
AU2020296933A1 (en) 2021-12-02
CO2021016967A2 (es) 2022-01-17
MX2021015889A (es) 2022-02-03
CA3139171A1 (en) 2020-12-24
US20220112199A1 (en) 2022-04-14
AR119207A1 (es) 2021-12-01
EP3986566A1 (en) 2022-04-27
JP2022537771A (ja) 2022-08-29
MA56507A (fr) 2022-04-27
WO2020254547A1 (en) 2020-12-24
US20220315591A1 (en) 2022-10-06
JP2022537772A (ja) 2022-08-29
EP3986566B1 (en) 2023-08-30
AR121167A1 (es) 2022-04-27
EP3986567A1 (en) 2022-04-27
IL287806A (en) 2022-01-01
BR112021024810A2 (pt) 2022-01-25
KR20220024096A (ko) 2022-03-03
CR20210614A (es) 2022-02-11
EP3986567B1 (en) 2023-08-30
ZA202108775B (en) 2022-09-28
CN113993591A (zh) 2022-01-28
CN113993590A (zh) 2022-01-28
PE20220807A1 (es) 2022-05-20

Similar Documents

Publication Publication Date Title
CL2021003191A1 (es) Inhibidores de tead y usos de los mismos
CL2021003190A1 (es) Inhibidores de tead y usos de los mismos
CO2021007068A2 (es) Degradadores de irak y usos de los mismos
CL2020003007A1 (es) Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017)
CL2021001330A1 (es) Nuevos compuestos heterocíclicos
CL2018001361A1 (es) Inhibidores éster de acc y usos de los mismos
CO2022008406A2 (es) Degradadores de irak y usos de los mismos
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
CO2019009373A2 (es) Compuestos heterocíclicos útiles como inhibidores duales de atx/ca.
EA201890749A1 (ru) ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) И ИХ ПРИМЕНЕНИЕ
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CL2021000361A1 (es) Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa
CO2021013339A2 (es) Degradadores de stat y usos de los mismos
CO2020015747A2 (es) Analogos de rapamicina y usos de los mismos
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
CO2022008662A2 (es) Degradadores de smarca y usos de los mismos
CL2022000019A1 (es) Nuevos compuestos heterocíclicos
CO2022002336A2 (es) Compuestos heterocíclicos
CO2023014721A2 (es) Compuestos heterocíclicos
BR112018071592A8 (pt) inibidores de erbb e usos dos mesmos
UY38759A (es) Tienilhidroxiisoxazolinas y derivados de las mismas
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1